Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.


High blood pressure (hypertension)

There are around 20 million people in Germany with high blood pressure (hypertension), making it once of the most widespread diseases in the country.1 High blood pressure does not initially cause any symptoms but can lead to severe complications such as heart attack and stroke, heart failure and renal failure or retinal damage. Symptoms such as headache, dizziness, insomnia or nausea may also occur in the longer term. Symptoms such as shortness of breath, severe sweating or visual disturbances are also reported in people with very high blood pressure.2

With every heartbeat the heart muscle pumps blood into the blood vessels radiating from the heart (arteries). If the flow of blood through the arteries is blocked, for example due to calcification of the arteries (arteriosclerosis), the heart needs to increase the pressure it produces.

Hypertension is diagnosed by measuring blood pressure.2 Systolic and diastolic blood pressure readings are taken. The optimal readings are less than 120 mmHg (systolic) and less than 80 mmHg (diastolic).2

Medical practitioners divide high blood pressure into primary and secondary hypertension. Primary hypertension may be genetically determined, but lack of exercise, stress, excessive salt intake, age, smoking etc. can also be risk factors. Secondary hypertension may be the result of organic conditions (kidney diseases) or metabolic disorders. In this case simply treating the underlying condition can have a positive effect on blood pressure.

Increased blood pressure should be monitored and treated. If a change in lifestyle such as stopping smoking, weight loss, exercise is not enough to address primary hypertension, antihypertensive drugs are used as long-term therapy.2 The most commonly used drugs are ACE inhibitors, AT1 antagonists, diuretics and calcium antagonists. 


1 Herz-Kreislauf-Erkrankungen » Herz & Kreislauf » Fachgebiete » Internisten im Netz » ( (Last accessed: 18.01.2024)

2 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Hypertonie – Langfassung, Version 1.0. 2023